| (Values in U.S. Thousands) | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Protokinetix Inc (PKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ProtoKinetix, Incorporated, a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. It is a medical research company whose mission is the advancement of human health care. The Company has developed a body of trade secrets and know-how relating to the development, use and manufacture of AAG(tm), including limited to the optimization of materials for efforts, and how to maximize sensitivity, speed-to-result, specificity, stability, purity and reproducibility. It owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGPs(tm). In scientific tests AAGPs(tm) have demonstrated the ability to enhance the health and extend the life of biologically sensitive cells which have been subjected to severe stress conditions under laboratory controlled test conditions. AAGPs(tm) are stable and non-toxic. The Company's competitors are substantially larger and have greater financial, research, manufacturing, and marketing resources. The Company's AAGP(tm) have commercial applications in markets and circumstances that fall under government regulations ranging from none to limited to extensive.
Fiscal Year End Date: 12/31